|
|
|
| The Non-Opioid Pain Therapeutics Summit provides a dedicated platform to harness the current momentum in the pain space. Attendees will be learning from companies with approvals such as Tonix and Vertex, exploring late-stage strategies from innovators like Latigo and Algiax, and uncovering discovery breakthroughs from Nocion and Axonis. Join discovery, preclinical, translational and clinical industry-based experts driving the future of non-opioid pain therapies. |
|
|
|
| Containment Liability: Choosing Assurance Or Insurance | Article | By Jason Ott, Flow Sciences Inc. | Engineering controls designed to mitigate exposure and create separation between the operator and toxic material are available in many forms, all with their own unique advantages and risks. |
|
|
|
| Getting To The Heart Of CDMO Tech Transfer Excellence | Article | Bora Pharmaceuticals | Explore five key factors that drive a seamless and efficient technology transfer, highlighting how a culture of technical expertise, customer focus, and operational flexibility is crucial to success. |
|
|
|
|
By Michele M. Simkin, Foley & Lardner | With explosive demand, expanding indications, and rapid innovation, the GLP-1 revolution is reshaping dealmaking. Here's a practical guide for companies negotiating M&A in this arena. | |
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
|
|
|
|
| Use Of Reconstructed Tissue And 3D Printed CT-Based Nasal Casts | Application Note | By Amegashie, A. LaBarge, W. Collins, AV. Resek, A. Volmer, JB, MedPharm | Reconstructed nasal epithelium and CT-based 3D nasal casts provide more predictive, physiologically relevant models for assessing nasal drug delivery, improving accuracy in formulation development. |
|
|
|
| Designing Shelf-Stable, Dry Powder Vaccines To Improve Global Access | Article | By Sana Hosseini and Kim Shepard, Lonza, and John Chen, Access to Advanced Healthcare Institute | Spray dry technology is being leveraged to create shelf-stable, dry-powder vaccines to treat and prevent the spread of tuberculosis which could significantly improve our global response to disease. |
|
|
| Reshaping Drug Development With 3D Screen Printing | Q&A | Adare Pharma Solutions | Steven Facer and Laxxon Medical COO Klaus Kühne describe the capabilities of 3D screen printing for pharmaceutical production. Explore prototyping, IP protection, release profile possibilities, and more. |
|
|
|
| Revolutionizing Pharma Validation With AI | Article | Aizon | Validation in GxP environments is often the bottleneck in digital transformation—manual, repetitive, and complex. One company's Intelligent Agents are transforming that process. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Connect With Pharmaceutical Online: |
|
|
|